Lilly turns to Amylin
Lilly will collaborate with Amylin on the development of AC2993 for type 2 diabetes, following Lilly's decision not to pursue Phase III studies of its in-house glucagon-like peptide-1 analogue. Lilly opted not to proceed to Phase III with its drug because of a technical failure in the formulation that caused adverse effects at the injection site, company says. AC2993 has a similar mechanism of action and is in Phase III; the companies hope to file an NDA in 2004. Agreement calls for Lilly to make an $80 mil. upfront payment and purchase $30 mil. in equity. Amylin will receive up to $215 mil. in additional milestone payments, and companies will split U.S. profits equally. Amylin previously worked with Johnson & Johnson on the development of Symlin (pramlintide), but J&J withdrew from the agreement...
You may also be interested in...
Amylin is eyeing a mid-2004 filing date for its exenatide NDA
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong
Exclusive: How are import/export restrictions both within and outside the European Union affecting the food supplements industry supply chain? HBW Insight speaks to Food Supplements Europe and the International Alliance of Dietary/Food Supplements Associations to find out.